Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody
Biotech
Regeneron posts positive ph. 2 POTS data, eyes pivotal trial
Regeneron has posted positive data on baloncibart in POTS, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
Nick Paul Taylor
Nov 13, 2026 3:31am
Spyre bolsters ulcerative colitis ambitions with ph. 2 win
Jun 15, 2026 3:19pm
Amgen loses in Harbour antibody patent case, ordered to pay $20M+
Jun 15, 2026 10:34am
Starry-eyed Star blazes forward with $125M funding boost
Sep 30, 2025 6:30am
'One of the lucky few': Bicara CEO on last year's $326M IPO
Apr 14, 2025 3:59pm
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
Dec 17, 2024 10:30am